Flow cytometry enables rapid, multiparameter analysis of heterogeneous cell populations on a cell-by-cell basis. IMDNA supports research and translational programs using conventional and multicolor flow cytometry for immunophenotyping, immune-cell profiling, biomarker discovery, intracellular signaling, functional assays, cell-state characterization, treatment-response studies, and cell-based analytical development.
Our scientific approach integrates biological question → sample strategy → marker selection → clone/fluorochrome architecture → staining optimization → instrument standardization → compensation or spectral unmixing → gating strategy → analytical validation → QC → interpretation and transfer. This systems-level approach reflects the fact that flow-cytometry performance depends simultaneously on sample quality, reagent behavior, instrument setup, panel design, acquisition, and analysis.
CLSI H62 emphasizes that flow-cytometric assays require a validation approach tailored to cellular measurands because the technology does not usually rely on classical soluble-analyte calibration curves and fully characterized cellular reference materials are often limited. Assay performance is therefore built from coordinated control of preanalytical, analytical, and postanalytical variables.
Identify and quantify multiple cell populations within complex blood, bone marrow, PBMC, tissue, culture, or investigator-defined research samples.
Measure several surface, intracellular, activation, differentiation, signaling, or functional markers simultaneously in individual cells.
Develop acquisition and gating strategies for low-frequency populations when sample quality, event count, marker specificity, and analytical precision support the research objective.
Evaluate cytokine production, proliferation, viability, apoptosis, receptor signaling, degranulation, cytotoxic potential, activation, or other investigator-selected cellular responses.
IMDNA can develop flow-cytometry strategies around the biology of the study rather than forcing projects into a fixed panel.
Naïve, memory, effector, helper, regulatory, activation, exhaustion, cytotoxic, and differentiation-associated phenotypes.
Maturation, activation, memory, plasmablast/plasma-cell–associated phenotypes, class-switching, and regulatory research markers.
Activation, maturation, inhibitory/activating receptors, cytotoxic phenotype, degranulation, and functional-response studies.
Monocytes, dendritic-cell populations, granulocyte-associated phenotypes, activation states, and inflammatory marker expression.
Research phenotyping of hematopoietic or investigator-defined stem/progenitor populations using appropriate marker combinations.
Abnormal population characterization, lineage-associated markers, maturation patterns, aberrant phenotypes, and research monitoring strategies.
Tumor-immune interaction, checkpoint markers, infiltrating immune populations, activation/suppression phenotypes, and therapy-response research.
Immune-cell subset changes, activation state, regulatory-cell biology, cytokine-producing populations, and inflammatory pathways.
Immune reconstitution, activation, cytotoxicity, regulatory-cell populations, exhaustion, and transplant-associated immune research.
Basophil activation, T-cell responses, B-cell phenotypes, immune-regulatory populations, and allergen-associated cellular responses.
Phenotype, viability, activation, memory, exhaustion, transduction-associated markers, and research characterization of engineered cells.
Compare cellular phenotypes before and after biologics, small molecules, immunotherapies, stimulation, or other experimental interventions.
Reliable immunophenotyping requires control of the complete workflow from sample handling through biological interpretation.
A strong multicolor panel is not simply a list of antibodies. Marker biology, antigen density, co-expression, fluorochrome brightness, spectral overlap, tandem-dye stability, detector sensitivity, spillover spreading, sample autofluorescence, clone behavior, fixation/permeabilization, and biological hierarchy all influence panel performance.
Define which markers identify lineage, differentiation, activation, function, exclusion, viability, or biological state and how those markers are co-expressed.
Choose antibody clones based on target specificity, epitope accessibility, fixation/permeabilization compatibility, staining quality, and available technical evidence.
Match bright fluorochromes to low-density or critical markers and reserve lower-brightness channels for highly expressed markers where appropriate.
Consider spectral spillover and spreading error between co-expressed markers rather than evaluating fluorescence overlap only by compensation values.
Evaluate full-panel performance because antibody/fluorochrome behavior can change when reagents are combined into a complex panel.
Use known positive, negative, stimulated, unstimulated, or other biologically informative samples when available to establish expected staining behavior.
ICSH/ICCS guidance emphasizes that sample type, anticoagulant, stability, processing, staining, fixation, permeabilization, time, and temperature are integral parts of a flow-cytometry assay. These variables can alter antigen expression, cell recovery, viability, scatter, and measured population frequencies.
| Preanalytical Variable | Why It Matters | IMDNA Support May Include |
|---|---|---|
| Sample Type | Whole blood, PBMCs, bone marrow, tissue, cell culture, and other matrices differ in cell composition, processing needs, autofluorescence, and stability. | Sample-specific workflow development, marker suitability review, validation-support planning. |
| Anticoagulant / Collection | Collection conditions can influence activation state, cell morphology, receptor expression, and sample stability. | Collection-condition comparison and predefined sample-acceptance planning. |
| Time to Staining / Acquisition | Delayed processing can change viability, antigen density, scatter, and population distribution. | Stability studies, time-window definition, storage-condition evaluation. |
| Red-Cell Lysis / Washing | Lysis and wash conditions can affect recovery, fragile populations, background, and cell loss. | Workflow optimization and comparison of technically appropriate preparation strategies. |
| Fixation / Permeabilization | Intracellular staining requires conditions that preserve target epitopes while enabling antibody access. | Protocol development, clone compatibility review, intracellular panel optimization. |
| Cell Viability | Dead or damaged cells can increase nonspecific staining and distort analysis. | Viability-dye strategy, sample-quality criteria, gating-support development. |
CLSI H62 specifically addresses instrument qualification, standardization, monitoring, and QC. EuroFlow demonstrated that standardized instrument settings, fluorescence compensation, sample preparation, SOPs, and panel design can substantially improve reproducibility across laboratories.
Document lasers, optical filters, detector configuration, acquisition parameters, thresholding, flow rate, and other instrument-specific settings used for the method.
Use appropriate QC materials or instrument-monitoring procedures to identify changes in optical, fluidic, or detector performance over time.
Where multi-instrument or multi-site comparability is important, establish reproducible target settings or other instrument-standardization strategies appropriate to the platform.
Use suitable single-color controls that adequately represent fluorochrome emission and generate reliable compensation matrices.
For spectral systems, use appropriate reference controls for each fluorochrome and account for autofluorescence when the platform and analysis require it.
Review whether antibody lots, instrument service, detector changes, software updates, or other changes require comparison or bridging before routine continuation.
Compensation corrects for fluorochrome emission detected in channels other than the intended detector. Accurate compensation requires suitable single-stained controls, stable instrument settings, and controls that are sufficiently bright and representative of the reagent used in the experiment.
Spectral instruments use the measured emission profile across multiple detectors to mathematically separate fluorochromes. Panel design still requires attention to spectral similarity, reference controls, fluorochrome stability, autofluorescence, and the biological co-expression of markers.
Gating determines which events are interpreted as biological populations. A reproducible assay should document gating logic, population hierarchy, exclusion rules, control use, and analyst decision points rather than treating gating as an undocumented post-acquisition step.
Build population identification logically from broad quality gates toward increasingly specific phenotypes.
Use suitable pulse-geometry parameters where needed to reduce interpretation of aggregates as single cells.
Exclude nonviable events where scientifically appropriate because dead cells may show altered scatter and nonspecific fluorescence.
Use FMO controls selectively when boundary placement for dim or continuously expressed markers is difficult in a complex panel.
Use known negative or positive populations when available to anchor gating decisions and monitor biologically expected staining.
Standardized templates improve consistency, but biologically complex or abnormal samples may require expert review rather than blind application of static gates.
CLSI H62 provides a fit-for-purpose framework for validation of cell-based fluorescence assays, including preexamination variables, assay optimization, instrument qualification, QC, analytical validation, data review, and retention. ICSH/ICCS guidelines further describe challenges unique to cellular measurands, including limited reference standards and difficulty creating samples spanning different cell frequencies or antigen-expression levels.
Evaluate repeatability and reproducibility across replicates, runs, operators, days, instruments, lots, or sites as appropriate.
Where a suitable comparator exists, evaluate agreement with another method, reference approach, consensus classification, or expected biological assignment.
For low-frequency populations or dim markers, evaluate detection capability with attention to event count, background, gating uncertainty, and biological variability.
Assess marker specificity, nonspecific staining, cross-reactivity, spillover-related misclassification, and phenotype-definition logic.
Determine whether delayed processing, storage, fixation, temperature, or other handling changes influence measured results.
Evaluate whether antibody or reagent lot changes materially alter staining intensity, population separation, or classification.
Challenge realistic changes in staining time, temperature, cell concentration, wash steps, acquisition settings, or sample handling.
Evaluate analyst-to-analyst or template-to-template variation when gating and interpretation contribute materially to the final research readout.
Low-frequency population analysis depends on total acquired events, background, specificity of the phenotype, sample quality, cell recovery, instrument stability, gating uncertainty, and the biological distribution of the target population. Event count alone does not establish analytical sensitivity. IMDNA can help design rare-event workflows around predefined biological populations, adequate controls, acquisition goals, repeatability, and fit-for-purpose analytical criteria.
The MIFlowCyt framework was developed to improve the completeness and reproducibility of flow-cytometry reporting by documenting samples, instruments, reagents, data acquisition, analysis, and results. For research programs, transparent documentation strengthens cross-study comparison and technology transfer.
Document sample source, collection, processing, storage, cell preparation, stimulation, treatment, and other experimental context.
Record marker, clone, fluorochrome, manufacturer/supplier, lot where relevant, concentration/titration, and staining conditions.
Document instrument model, laser/filter configuration, QC state, detector settings or standardized targets, and acquisition software.
Preserve gating hierarchy, transformations, compensation/unmixing, thresholds, population definitions, software version, and analyst-specific decisions.
Retain FCS files and associated metadata so analyses can be re-reviewed, audited, or reprocessed when scientifically appropriate.
Use controlled SOPs, panel maps, instrument settings, gating templates, QC criteria, and training materials when moving a method between teams or sites.
Marker selection, clone review, fluorochrome assignment, panel hierarchy, and full-panel optimization.
Optimize reagent concentration to improve separation while reducing nonspecific background and unnecessary reagent excess.
Lineage, differentiation, activation, trafficking, checkpoint, maturation, and cell-state marker analysis.
Cytokines, transcription factors, phospho-signaling, proliferation, apoptosis, and other intracellular targets with appropriate fixation/permeabilization.
Activation, degranulation, intracellular cytokine response, proliferation, viability, apoptosis, receptor occupancy, or investigator-defined functional endpoints.
Fit-for-purpose precision, sensitivity, specificity, stability, robustness, lot comparison, and data-analysis studies.
Instrument monitoring, standardized settings, reagent controls, compensation/unmixing resources, and run-level QC workflows.
SOPs, panel maps, reagent lists, instrument settings, gating strategies, training, comparison studies, and post-transfer technical support.
IMDNA provides scientific, technical, assay-development, analytical-validation, documentation, training, QC, troubleshooting, and non-regulatory flow-cytometry support based on the needs of each research or laboratory project. Support may include panel design, antibody and fluorochrome selection, sample preparation, staining optimization, instrument-standardization planning, compensation or spectral-unmixing strategy, gating, controls, validation-study design, data review, documentation, and technology transfer.
Flow-cytometry assay design and validation must be matched to the intended use, sample type, instrument, marker biology, reporting approach, and laboratory environment. Not every marker, control, validation parameter, or gating strategy described on this page is appropriate for every assay.
IMDNA is not a regulatory, licensing, accreditation, certification, legal, governmental, or inspecting authority. For projects intended for clinical or regulated use, the responsible laboratory, sponsor, product owner, or manufacturer determines applicable requirements, approves protocols and acceptance criteria, performs or authorizes required validation/verification, approves the final method, and determines whether patient testing may be performed.
References to CLSI, ICSH, ICCS, EuroFlow, FDA, or other scientific and standards organizations are provided for scientific and informational context only and do not imply endorsement, approval, affiliation, certification, or sponsorship of IMDNA.
The following sources support the scientific framework used on this page. Their applicability depends on assay purpose, laboratory setting, instrument, and regulatory context.
Tell IMDNA about your research question, cell population, sample type, markers of interest, available instrument configuration, number of colors, expected antigen density, intracellular or surface targets, functional readouts, controls, and study objectives. Our scientific team can help develop a customized flow-cytometry and immunophenotyping workflow covering marker selection, panel design, staining optimization, instrument setup, compensation/unmixing, gating, analytical validation, QC, documentation, and technology transfer.